The JAK1 Knockout Ca Ski Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout population with targeted disruptions in the JAK1 gene within the Ca Ski cervical carcinoma cell line. This heterogeneous cell pool enables loss-of-function analysis without clonal selection, maintaining genetic diversity ideal for population-based studies.
The Ca Ski line originates from an epidermoid carcinoma metastasis and serves as a classic model for HPV-16-positive cervical cancer. These epithelial cells harbor integrated HPV-16 genomes and express viral oncoproteins, making them valuable for exploring host-pathogen signaling interactions.
JAK1 encodes a non-receptor tyrosine kinase that functions as a critical signal transducer for multiple cytokine receptors, including those for IL-2, IL-6, and interferons. Upon cytokine stimulation, JAK1 becomes activated and phosphorylates the intracellular domains of the receptor, enabling recruitment and phosphorylation of STAT transcription factors??primarily STAT1, STAT3, STAT5, and STAT6. Phosphorylated STATs dimerize and enter the nucleus to modulate the expression of target genes, such as SOCS family members (SOCS3), MYC, CCND1 (Cyclin D1), and BCL2L1 (Bcl-xL). JAK1 also interacts with SOCS proteins that provide negative feedback and with PI3K, linking to parallel signaling cascades. A well-characterized pathway is IL-6 signaling through the IL-6R/gp130 receptor complex, which recruits JAK1 and JAK2, ultimately activating STAT3 to induce SOCS3 and promote cell survival via Bcl-xL and proliferation via Cyclin D1. In this capacity, JAK1 orchestrates cellular responses to cytokines, governing proliferation, apoptosis, and immune functions.
Cervical cancer progression is driven by HPV oncoproteins, but host cytokine networks such as IL-6/STAT3 signaling significantly influence the tumor microenvironment and malignant phenotypes. JAK1 knockout in Ca Ski cells ablates a critical node in these cascades, enabling researchers to dissect the role of cytokine-mediated signals in sustaining HPV oncogene expression, promoting cell proliferation, and evading immune destruction. This polyclonal model thus provides insights into potential therapeutic vulnerabilities within the JAK-STAT pathway in HPV-positive cancers.
Typical downstream analyses include Western blotting for phosphorylated STAT1, STAT3, and STAT5 to verify pathway inactivation; RT-qPCR to measure transcript levels of SOCS3, MYC, and BCL2L1; functional assays such as MTT proliferation, Annexin V apoptosis, and cell cycle distribution analysis; and phospho-flow cytometry to assess signaling dynamics following cytokine stimulation. Drug sensitivity profiling with JAK inhibitors like ruxolitinib, transcriptome-wide RNA-seq, and co-culture systems to evaluate immune interactions further extend the model??s utility. This product supports both mechanistic studies and translational research in cervical cancer and beyond. For additional details, please contact Ascent Research.
